PH12023550007A1 - Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome - Google Patents

Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Info

Publication number
PH12023550007A1
PH12023550007A1 PH1/2023/550007A PH12023550007A PH12023550007A1 PH 12023550007 A1 PH12023550007 A1 PH 12023550007A1 PH 12023550007 A PH12023550007 A PH 12023550007A PH 12023550007 A1 PH12023550007 A1 PH 12023550007A1
Authority
PH
Philippines
Prior art keywords
inhibitor
tourette syndrome
phosphodiesterase
treatment
formula
Prior art date
Application number
PH1/2023/550007A
Other languages
English (en)
Inventor
George Garibaldi
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of PH12023550007A1 publication Critical patent/PH12023550007A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PH1/2023/550007A 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome PH12023550007A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035310P 2020-06-05 2020-06-05
US202163160302P 2021-03-12 2021-03-12
PCT/EP2021/065074 WO2021245280A1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Publications (1)

Publication Number Publication Date
PH12023550007A1 true PH12023550007A1 (en) 2024-03-11

Family

ID=76325557

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/550007A PH12023550007A1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Country Status (13)

Country Link
US (2) US11883385B2 (https=)
EP (1) EP4161526A1 (https=)
JP (2) JP7748974B2 (https=)
KR (2) KR20250171459A (https=)
CN (2) CN116137811B (https=)
AU (1) AU2021285225A1 (https=)
BR (1) BR112022024751A2 (https=)
CA (1) CA3180793A1 (https=)
CL (2) CL2022003400A1 (https=)
IL (1) IL298713A (https=)
MX (1) MX2022015400A (https=)
PH (1) PH12023550007A1 (https=)
WO (1) WO2021245280A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544364B2 (en) * 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
WO2022162193A1 (en) * 2021-01-28 2022-08-04 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder
WO2026068583A1 (en) * 2024-09-25 2026-04-02 Noema Pharma Ag Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1723134A2 (en) * 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8349824B2 (en) * 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
BR112014004310B8 (pt) * 2011-08-25 2023-04-18 Merck Sharp & Dohme Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
PL3919060T3 (pl) * 2012-07-12 2025-10-20 Emalex Biosciences, Inc. Ekopipam do leczenia zespołu tourette'a
NZ708593A (en) * 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
MY169128A (en) * 2013-04-30 2019-02-18 Hoffmann La Roche Pd-catalyzed coupling of pyrazole amides

Also Published As

Publication number Publication date
CN116137811A (zh) 2023-05-19
KR102892626B1 (ko) 2025-11-28
CA3180793A1 (en) 2021-12-09
CN116137811B (zh) 2026-01-09
BR112022024751A2 (pt) 2023-03-07
CN121891333A (zh) 2026-04-21
IL298713A (en) 2023-02-01
CL2022003400A1 (es) 2023-07-28
US20260076950A1 (en) 2026-03-19
JP2025183391A (ja) 2025-12-16
US11883385B2 (en) 2024-01-30
AU2021285225A1 (en) 2023-01-19
WO2021245280A1 (en) 2021-12-09
JP7748974B2 (ja) 2025-10-03
EP4161526A1 (en) 2023-04-12
MX2022015400A (es) 2023-03-16
WO2021245280A9 (en) 2022-01-27
CL2025002636A1 (es) 2025-11-28
US20230149372A1 (en) 2023-05-18
JP2023528896A (ja) 2023-07-06
KR20230040978A (ko) 2023-03-23
KR20250171459A (ko) 2025-12-08

Similar Documents

Publication Publication Date Title
CR20230310A (es) Inhibidores de prmt5
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12021500049A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
WO2024123913A8 (en) Kras(g12v) inhibitors
GEP20267860B (en) Condensed tryciclic pyrroles as alpha-1 antitrypsin modulators
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2022008103A (es) Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
MX2025010928A (es) Compuestos de alquinil quinazolina
PH12023550007A1 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
TW200510380A (en) Mitotic kinesin inhibitors
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
TW200626601A (en) Novel compounds
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
PH12023550160A1 (en) Combinations for the Treatment of Cancer
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
DE60306546D1 (de) Entzündungshemmende 3-arylthio-3-thiazolylalkylamine
ZA202400821B (en) Inhibitors of transglutaminases
TW200639159A (en) Treatment of pain
UA97483C2 (ru) Производное пиримидина в качестве ингибитора pi3k и его применение
JOP20230275A1 (ar) معدلات trex1